NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/29/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization3.58 mln
Float0.21 mln
Earnings Date06/12/2026
Piotroski F-Score
3
/ 9
Below average
Relative Strength
1
/ 100
Severely lagging
Debt / Equity
0.00
Debt-free
ROE
-212
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Clearmind Medicine Inc. is a clinical-stage pharmaceutical company based in Vancouver, Canada, focused on developing new treatments for conditions that have few effective options today, including alcohol dependency, eating disorders, obesity, anxiety, PTSD, and depression. Its lead compound, MEAI, is being studied both as a medical treatment and as a consumer alternative to alcohol, while its drug candidate CM-CMND-001 is currently in Phase I/IIa clinical trials. The company works with several research and development partners, including the Hebrew University of Jerusalem and SciSparc Ltd., to advance its pipeline across a range of metabolic and mental health conditions.
